Skip to main content
eScholarship
Open Access Publications from the University of California

UCLA

UCLA Previously Published Works bannerUCLA

The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.

  • Author(s): Skinner-Adams, Tina S
  • Butterworth, Alice S
  • Porter, Kimberly A
  • D'Amico, Ronald
  • Sawe, Fred
  • Shaffer, Doug
  • Siika, Abraham
  • Hosseinipour, Mina C
  • Stringer, Elizabeth
  • Currier, Judith S
  • Chipato, Tsungai
  • Salata, Robert
  • Lockman, Shahin
  • Eron, Joseph J
  • Meshnick, Steven R
  • McCarthy, James S
  • et al.
Abstract

HIV protease inhibitors (PIs) show antimalarial activity in vitro and in animals. Whether this translates into a clinical benefit in HIV-infected patients residing in malaria-endemic regions is unknown. We studied the incidence of malaria, as defined by blood smear positivity or a positive Plasmodium falciparum histidine-rich protein 2 antigen test, among 444 HIV-infected women initiating antiretroviral treatment (ART) in the OCTANE trial (A5208; ClinicalTrials.gov: NCT00089505). Participants were randomized to treatment with PI-containing vs. PI-sparing ART, and were followed prospectively for ≥48 weeks; 73% also received cotrimoxazole prophylaxis. PI-containing treatment was not associated with protection against malaria in this study population.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View